Global Antimicrobial Resistance Surveillance System (GLASS)

Implementation questionnaire
GLASS Implementation Questionnaire

WHO Region

Country

Year

1. Has a National Coordination Centre (NCC) been established?
   o Yes, with a mandate and terms of reference in line with the GLASS manual.
   If yes, please provide the name and full address of institution
     Name of Institution
     Address of Institution
   o In progress
   o No

2. Has a National Focal Point been assigned (responsible for liaison with GLASS/WHO)?
   o Yes
   o In progress
   o No

   If yes, please provide the full name and contact details of the Focal Point
     First name
     Family name
     Address
     Telephone
     Email address
3. Have plans been agreed to implement and strengthen antimicrobial resistance surveillance (AMR) surveillance, including participation in GLASS?
   o Yes, with budget
   If yes and in the public domain, please provide the web link to the document
   
   o Yes, but NO budget
   If yes and in the public domain, please provide the web link to the document
   
   o No
   o Unknown

4. Has a National Reference Laboratory(s) (NRL) been designated to support national AMR surveillance?
   o Yes
   o No
   o Unknown
   If yes, please provide the name of laboratory
   
   Address of laboratory

5. Does the national reference laboratory participate in an external quality assurance (EQA) scheme?
   o Yes
   o No
   o Unknown
6. Which antimicrobial susceptibility testing (AST) standards are applied in your country?
   - CLSI (Clinical and Laboratory Standards Institute)
   - EUCAST (European Committee on Antimicrobial Susceptibility Testing) Other
   If other, please specify ____________________________
   - Unknown

7. How many surveillance sites have been identified that fulfil the requirements to collect and report data according to GLASS manual?
   Number of hospitals ___________
   Number of outpatient facilities ___________
   - Unknown

8. How many designated surveillance sites have provided data for submission to GLASS in this reporting period?
   Number of hospitals ___________
   Number of outpatient facilities ___________
   - Unknown

9. How many laboratories that perform AST are providing support to participating surveillance sites?
   Number of laboratories ___________
   - Unknown

10. Does the national AMR programme organize and run external quality assurance for all laboratories participating in GLASS
    - Yes
    - No
    - For some laboratories
11. If yes, does this EQA cover both bacterial identification and AST?
   o Yes
   o No, only bacterial identification
   o No, only AST

12. Which pathogens are covered by the EQA?
   o All priority pathogens listed in the GLASS manual
   o Some, but not all priority pathogens
   o Unknown

13. Are AMR surveillance standards and guidelines that incorporate GLASS standards available in the country?
   o Yes
   o No
   o Unknown